Table 3.
Proportion of resistance to pyrazinamide and second-line anti-TB drugs among patients with MDR-TB, Djibouti nationwide drug-resistance survey, 2014–2015.
| New cases (n = 14) | Previously treated cases (n = 20) | Total (n = 34) | |||||
|---|---|---|---|---|---|---|---|
| Drug | Resistance profile | n | % (CI95%) | n | % (CI95%) | n | % (CI95%) |
| PZA | R | 10 | 71.43 (45.4; 88.3) | 13 | 65.0 (43.3; 81.9) | 23 | 67.7 (50.8–80.9) |
| AMK/KAN | R | 2 | 14.3 (4.0; 39.9) | 4 | 20.0 (8.1; 41.6) | 6 | 17.7 (8.4; 33.5) |
| CAPREO | R | 3 | 21.4 (7.6; 47.6) | 7 | 35.0 (18.1; 56.7) | 10 | 29.4 (16.8; 46.2) |
| FQs | R | 0 | 0 (0.0; 21.5) | 0 | 0 (0.0; 16.1) | 0 | 0 (0.0; 10.2) |
PZA: pyrazinamide; AMK: amikacin; KAN: kanamycin; CAPREO: capreomycin; FQs: fluoroquinolones; R: resistant.